Comparing Advanced Biomedical Technologies (OTCMKTS:ABMT) and Veracyte (NASDAQ:VCYT)

Veracyte (NASDAQ:VCYT) and Advanced Biomedical Technologies (OTCMKTS:ABMT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Veracyte and Advanced Biomedical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veracyte	12.83%	8.05%	7.38%
Advanced Biomedical Technologies	N/A	N/A	N/A

Volatility & Risk

Veracyte has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Advanced Biomedical Technologies has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Earnings and Valuation

This table compares Veracyte and Advanced Biomedical Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15 million	4.96	$66.35 million	$0.83	38.86
Advanced Biomedical Technologies	N/A	N/A	N/A	N/A	N/A

Veracyte has higher revenue and earnings than Advanced Biomedical Technologies.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Veracyte and Advanced Biomedical Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1	3	3	0	2.29
Advanced Biomedical Technologies	0	0	0	0	0.00

Veracyte presently has a consensus price target of $44.20, suggesting a potential upside of 37.05%. Given Veracyte’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Veracyte is more favorable than Advanced Biomedical Technologies.

Summary

Veracyte beats Advanced Biomedical Technologies on 8 of the 8 factors compared between the two stocks.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

About Advanced Biomedical Technologies

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.